Global markets
Eli Lilly acquires Centessa for $6.3B plus $1.5B CVR
Lilly scoops up Centessa Pharmaceuticals for $6.3B upfront plus $1.5B contingent payout, securing OX2R agonist cleminorexton pipeline in sleep-wake disorders.
Primary sources · 1
Lilly scoops up Centessa Pharmaceuticals for $6.3B upfront plus $1.5B contingent payout, securing OX2R agonist cleminorexton pipeline in sleep-wake disorders.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.